Cafotrex Injection contains Methotrexate 50mg/2ml, a potent injectable anticancer and immunosuppressive drug used in the treatment of hematologic malignancies such as leukemia and lymphoma, solid tumors like breast cancer, and autoimmune disorders including rheumatoid arthritis and psoriasis.
Methotrexate works by inhibiting dihydrofolate reductase, preventing DNA synthesis in rapidly dividing cells, and modulating immune system activity. Its precise cytotoxic and immunosuppressive effects make it essential in oncology and autoimmune therapy protocols.
For distributors and healthcare suppliers, Cafotrex Injection is a high-demand specialty injection, supplied to oncology hospitals, autoimmune clinics, and tertiary care centers. Regular use in chemotherapy and chronic autoimmune management ensures sustained market demand.
Adding Cafotrex Injection to your oncology and immunosuppressive therapy portfolio creates strong opportunities in hospital supply chains, specialty pharmacies, export markets, and third-party manufacturing. Its proven clinical effectiveness, critical therapeutic role, and prescriber trust make it a valuable addition to pharmaceutical distribution portfolios.